Mineralys Therapeutics will announce Q1 2025 financial results on May 12, 2025, via conference call and webcast.
Quiver AI Summary
Mineralys Therapeutics, Inc. announced that it will release its financial results for the first quarter ending March 31, 2025, after the market closes on May 12, 2025. A conference call will take place at 4:30 p.m. ET on the same day, with details provided for both domestic and international callers. The company focuses on developing treatments for conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea, primarily using its lead product, lorundrostat, which is a highly selective aldosterone synthase inhibitor. Mineralys is headquartered in Radnor, Pennsylvania and was founded by Catalys Pacific. More information can be found on their website and social media platforms.
Potential Positives
- The announcement of the upcoming financial results reflects transparency and informs stakeholders about the company's financial performance timeline.
- The company is focused on developing treatments for significant health issues such as hypertension, chronic kidney disease, and obstructive sleep apnea, highlighting its commitment to addressing critical medical needs.
- Mineralys Therapeutics' initial product candidate, lorundrostat, is positioned as a cutting-edge treatment option, which may enhance the company's reputation and attract interest from investors.
Potential Negatives
- The press release highlights that the company is in a clinical stage, which may indicate a lack of approved products or market presence, potentially leading to limited revenue and increased investor concerns.
- The timing of the financial results announcement may indicate financial uncertainty, as the market may interpret the need for a future report as a signal of potential losses or operational challenges.
FAQ
When will Mineralys Therapeutics announce its financial results?
Mineralys Therapeutics will report its financial results for Q1 2025 on May 12, 2025, after market close.
How can I access the Mineralys Therapeutics conference call?
You can access the conference call by dialing 1-800-717-1738 (Domestic) or 1-646-307-1865 (International) with Conference ID 53214.
What is the primary focus of Mineralys Therapeutics?
Mineralys Therapeutics focuses on developing medicines for hypertension, chronic kidney disease, and obstructive sleep apnea.
What is lorundrostat developed by Mineralys Therapeutics?
Lorundrostat is a proprietary orally administered aldosterone synthase inhibitor targeting cardiorenal conditions.
Where is Mineralys Therapeutics headquartered?
Mineralys Therapeutics is headquartered in Radnor, Pennsylvania.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MLYS Insider Trading Activity
$MLYS insiders have traded $MLYS stock on the open market 16 times in the past 6 months. Of those trades, 4 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $MLYS stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA purchased 1,296,296 shares for an estimated $17,499,996
- SRINIVAS AKKARAJU purchased 600,000 shares for an estimated $8,100,000
- BIOCAPITAL GP, LLC SAMSARA purchased 600,000 shares for an estimated $8,100,000
- BRIAN TAYLOR SLINGSBY purchased 259,259 shares for an estimated $3,499,996
- DAVID MALCOM RODMAN (Chief Medical Officer) has made 0 purchases and 7 sales selling 97,645 shares for an estimated $1,502,657.
- JON CONGLETON (Chief Executive Officer) has made 0 purchases and 2 sales selling 33,652 shares for an estimated $352,885.
- ADAM SCOTT LEVY (CFO and Secretary) has made 0 purchases and 3 sales selling 21,514 shares for an estimated $227,548.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MLYS Hedge Fund Activity
We have seen 63 institutional investors add shares of $MLYS stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PICTET ASSET MANAGEMENT HOLDING SA added 1,214,373 shares (+inf%) to their portfolio in Q1 2025, for an estimated $19,284,243
- MILLENNIUM MANAGEMENT LLC added 1,002,941 shares (+1015.8%) to their portfolio in Q4 2024, for an estimated $12,346,203
- JENNISON ASSOCIATES LLC added 897,027 shares (+82.9%) to their portfolio in Q1 2025, for an estimated $14,244,788
- OCTAGON CAPITAL ADVISORS LP removed 600,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $7,386,000
- INTEGRAL HEALTH ASSET MANAGEMENT, LLC added 519,000 shares (+145.8%) to their portfolio in Q4 2024, for an estimated $6,388,890
- JPMORGAN CHASE & CO added 482,174 shares (+2251.5%) to their portfolio in Q4 2024, for an estimated $5,935,561
- ADAMS STREET PARTNERS LLC removed 402,847 shares (-26.3%) from their portfolio in Q4 2024, for an estimated $4,959,046
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MLYS Analyst Ratings
Wall Street analysts have issued reports on $MLYS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 04/02/2025
To track analyst ratings and price targets for $MLYS, check out Quiver Quantitative's $MLYS forecast page.
Full Release
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025.
| Monday, May 12 th @ 4:30 p.m. ET | |
| Domestic: | 1-800-717-1738 |
| International: | 1-646-307-1865 |
| Conference ID: | 53214 |
| Webcast: | Link |
A live webcast of the conference call may also be found on the “ News & Events ” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit
https://mineralystx.com
. Follow Mineralys on
LinkedIn
and
Twitter
.
Contact:
Investor Relations
[email protected]
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email:
[email protected]
